AstraZeneca is cutting 600 sales positions in the United States as part of its cost-cutting program. The cuts may lower spending, but the report gives no savings estimate or sales effect, so it shows no clear change for the company.
Fewer sales positions could lower costs, but they could also limit the company's sales reach. The report gives no expected savings or effect on sales, so it does not show a clear change for AstraZeneca.
Follow AstraZeneca (AZN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for AZN